Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Data Can Be Used to Improve Patient Decision Making and Address Disparities, Says Dr Ken Cohen
January 14th 2023Initiatives to address social determinants of health are likely to positively change the health care landscape, and better patient education can contribute to more favorable care choices says Ken Cohen, MD, director of translational research for Optum Care.
Read More
Dr Alonso V. Pacheco Discusses a Tool to Measure Chemotherapy Toxicity for Elderly Patients
January 13th 2023A tool to measure chemotherapy toxicity from the Cancer and Aging Research Group can help determine emergency department visits or hospitalization risk, especially for elderly patients, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
Read More
Dr Ken Cohen Offers Possible Solutions to Reducing Wasteful Health Care
January 12th 2023Creating new incentive models and transparently sharing data in a way that changes behaviors are 2 ways to reduce low-value care in the health care system, explains Ken Cohen, MD, director of translational research for Optum Care.
Read More
Impact of Patient Factors on Developing AML After MDS or CML; Ponatinib in Highly Resistant CP-CML
January 7th 2023Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.
Read More
FDA’s Lecanemab Approval Will Raise Pricing, Access Challenges, Says Dr Alvaro Pascual-Leone
January 6th 2023The FDA’s approval of lecanemab for Alzheimer disease is very important, but there will remain significant challenges around pricing and access that will need to be addressed to deliver on the promise the therapy actually represents, said Alvaro Pascual-Leone, MD, PhD, of Harvard Medical School.
Read More
PBMs Announce 2023 Coverage Plans for Adalimumab Biosimilars
January 1st 2023The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
Read More
Abstracts Highlight the Efficacy of BCL-2 Inhibitors in AML and CLL
December 29th 2022Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma
December 23rd 2022The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.
Read More
Aligning Payers and Providers for Value-Based Cancer Care Payments
December 9th 2022Lucy Langer, MD, MSHS, national medical director, oncology and genomics, MSHS, national medical director, oncology and genomics, UnitedHealthcare, discussed value-based contracting at the IVBM® session October 5, 2022.
Read More
Dr Kalin Clifford Outlines Research Into Alternative/Complementary Therapies for Dementia
December 7th 2022There is new data coming out on complementary and alternative therapies for dementia, including supplements, mindfulness techniques, exercise, music therapy, and more, said Kalin Clifford, PharmD, BCGP, BCPS, FASCP, associate professor, Geriatrics Division, Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy.
Read More
Some of the latest trends in the health-system pharmacy space are ones that have already been around for a while, and organizations will need to understand how to address them at the local level, explained Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University.
Read More
Dr Dena Behm Dillon on Treating Patients With HIV and Medication Affordability, Adherence
December 6th 2022Once patients with HIV start treatment, pharmacists can play a key role in addressing patient accessibility and affordability of HIV treatments and promoting adherence, said Dena Behm Dillon, PharmD, AAHIVP, HIV clinical pharmacy specialist, University of Iowa Health Care.
Read More
Dr Jawad Saleh: There Are Many Risk Factors for PONV
December 6th 2022There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of pharmacy services, Hospital for Special Surgery.
Read More
Pharmacists can play an important role in dispelling myths about vaccines, as well as identifying patients who are eligible for vaccinations that they haven’t yet received, said Jacinda C. Abdul-Mutakabbir, PharmD, MPH, AAHIVP, assistant professor of pharmacy practice, Loma Linda University.
Read More
Dr Scott Soefje Highlights the Decision to Implement IV Chemotherapy Robotic Technology
December 5th 2022Intravenous (IV) robotic technology brings advantages for pharmacy staff, but there are also accuracy issues with the technology. In addition, this technology will not be replacing a pharmacy technician job, said Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, director of pharmacy cancer care and assistant professor of pharmacy, Mayo Clinic.
Read More
US Biosimilars Substantially More Expensive Than Those in Germany, Switzerland
December 5th 2022Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
Read More
Dr Marie Chisholm-Burns to Receive Distinguished Leadership Award at ASHP Midyear
December 2nd 2022Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University, is receiving the award, which is presented to individuals who demonstrate excellence in pharmacy practice leadership.
Read More
At the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting & Exposition, Angela M. Hill, PharmD, CPh, RPh, professor and associate dean of clinical affairs; project director, WE-CARE, University of South Florida Taneja College of Pharmacy, will receive the ASHP-ABHP Joint Leadership award for her leadership in addressing health equities.
Read More
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More
FGFR Inhibitors Show Promise in Cholangiocarcinoma but Face Acquired Resistance
November 25th 2022There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ways to overcome this resistance.
Read More
Dr Emeline Aviki: Telehealth Allows Patients a Quick Return to Daily Life
November 19th 2022There is a major role for telehealth in oncology care, not only for its convenience but also for giving clinicians the ability to scale nononcologic visits, explained Emeline Aviki, MD, MBA, FACOG, assistant attending gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and lead of the MSKCC Affordability Working Group.
Read More